Lyra Net Debt To E B I T D A from 2010 to 2025
| LYRA Stock | USD 0.16 0 0.63% |
Net Debt To EBITDA | First Reported 2010-12-31 | Previous Quarter 0.10283429 | Current Value 0.0977 | Quarterly Volatility 1.50220498 |
Check Lyra Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lyra Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 3.1 M, Interest Income of 3.1 M or Depreciation And Amortization of 474.7 K, as well as many indicators such as Price To Sales Ratio of 8.32, Dividend Yield of 0.0 or PTB Ratio of 1.1. Lyra financial statements analysis is a perfect complement when working with Lyra Therapeutics Valuation or Volatility modules.
Lyra | Net Debt To E B I T D A |
Latest Lyra Therapeutics' Net Debt To E B I T D A Growth Pattern
Below is the plot of the Net Debt To E B I T D A of Lyra Therapeutics over the last few years. It is a leverage ratio that indicates a company's ability to pay off its incurred debt. It compares a company's net debt (total debt minus cash) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). Lyra Therapeutics' Net Debt To EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lyra Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Net Debt To E B I T D A | 10 Years Trend |
|
Net Debt To E B I T D A |
| Timeline |
Lyra Net Debt To E B I T D A Regression Statistics
| Arithmetic Mean | 2.21 | |
| Coefficient Of Variation | 68.00 | |
| Mean Deviation | 1.39 | |
| Median | 3.33 | |
| Standard Deviation | 1.50 | |
| Sample Variance | 2.26 | |
| Range | 3.3978 | |
| R-Value | (0.83) | |
| Mean Square Error | 0.76 | |
| R-Squared | 0.69 | |
| Significance | 0.000073 | |
| Slope | (0.26) | |
| Total Sum of Squares | 33.85 |
Lyra Net Debt To E B I T D A History
About Lyra Therapeutics Financial Statements
Lyra Therapeutics stakeholders use historical fundamental indicators, such as Lyra Therapeutics' Net Debt To E B I T D A, to determine how well the company is positioned to perform in the future. Although Lyra Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Lyra Therapeutics' assets and liabilities are reflected in the revenues and expenses on Lyra Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Lyra Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Debt To EBITDA | 0.10 | 0.10 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out the analysis of Lyra Therapeutics Correlation against competitors. For information on how to trade Lyra Stock refer to our How to Trade Lyra Stock guide.You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lyra Therapeutics. If investors know Lyra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lyra Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.43) | Revenue Per Share | Quarterly Revenue Growth 0.432 | Return On Assets | Return On Equity |
The market value of Lyra Therapeutics is measured differently than its book value, which is the value of Lyra that is recorded on the company's balance sheet. Investors also form their own opinion of Lyra Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Lyra Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lyra Therapeutics' market value can be influenced by many factors that don't directly affect Lyra Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lyra Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lyra Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lyra Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.